{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:06Z","timestamp":1792640286893,"version":"4.5.0"},"reference-count":71,"publisher":"European Respiratory Society (ERS)","issue":"167","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,10,15]]},"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:p>Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF) and contribute to lung function decline. Antibiotics are the mainstay in the treatment of exacerbations and chronic bacterial infection in CF. Inhaled antibiotics are effective in treating chronic respiratory bacterial infections and eradicating<jats:italic>Pseudomonas aeruginosa<\/jats:italic>from the respiratory tract, with limited systemic adverse effects. In the past decade, highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become a new therapy that partially corrects\/opens chloride transport in patients with selected CFTR mutations, restoring mucus hydration and improving mucociliary clearance. The recent triple CFTR modulator combination is approved for \u223c80\u201390% of the CF population and significantly reduces pulmonary exacerbations and improves respiratory symptoms and lung function. CFTR modulators have shifted the focus from symptomatic treatment to personalised\/precision medicine by targeting genotype-specific CFTR defects. While these are highly effective, they do not fully normalise lung physiology, stop inflammation or resolve chronic lung damage, such as bronchiectasis. The impact of these new drugs on lung health is likely to change the future management of chronic pulmonary infections in people with CF. This article reviews the role of inhaled antibiotics in the era of CFTR modulators.<\/jats:p>","DOI":"10.1183\/16000617.0154-2022","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:47:35Z","timestamp":1673434055000},"page":"220154","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Role of inhaled antibiotics in the era of highly effective CFTR modulators"],"prefix":"10.1183","volume":"32","author":[{"given":"J. Stuart","family":"Elborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2024102404093150000_32.167.220154.1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06697"},{"key":"2024102404093150000_32.167.220154.2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.chest.2018.10.006","article-title":"The clinical biology of cystic fibrosis transmembrane regulator protein: its role and function in extrapulmonary disease","volume":"155","author":"Liou","year":"2019","journal-title":"Chest"},{"key":"2024102404093150000_32.167.220154.3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jcf.2015.02.007","article-title":"Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis","volume":"14","author":"VanDevanter","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.4","doi-asserted-by":"publisher","DOI":"10.1186\/1755-7682-1-24"},{"key":"2024102404093150000_32.167.220154.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.060889"},{"key":"2024102404093150000_32.167.220154.6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1804OC"},{"key":"2024102404093150000_32.167.220154.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421"},{"key":"2024102404093150000_32.167.220154.9","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21301"},{"key":"2024102404093150000_32.167.220154.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.6.831"},{"key":"2024102404093150000_32.167.220154.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00248102"},{"key":"2024102404093150000_32.167.220154.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202059"},{"key":"2024102404093150000_32.167.220154.13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"7","author":"MacLusky","year":"1989","journal-title":"Pediatr Pulmonol"},{"key":"2024102404093150000_32.167.220154.14","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950070413"},{"key":"2024102404093150000_32.167.220154.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282403"},{"key":"2024102404093150000_32.167.220154.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"},{"key":"2024102404093150000_32.167.220154.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2010.10.003"},{"key":"2024102404093150000_32.167.220154.18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051062"},{"key":"2024102404093150000_32.167.220154.19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008319.pub3"},{"key":"2024102404093150000_32.167.220154.20","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/ppul.24511","article-title":"Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis","volume":"54","author":"McKinzie","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2024102404093150000_32.167.220154.21","unstructured":"U.S. Food & Drug Administration (FDA) . FDA Approves New Breakthrough Therapy for Cystic Fibrosis. www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis#:\u223c:text=Trikafta%20is%20approved%20for%20patients,of%20the%20cystic%20fibrosis%20population Date last accessed: 11 August 2022. Date last updated: 21 October 2019."},{"key":"2024102404093150000_32.167.220154.22","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024102404093150000_32.167.220154.23","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"2024102404093150000_32.167.220154.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.04.036"},{"key":"2024102404093150000_32.167.220154.25","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2147\/TCRM.S147164","article-title":"Triplet CFTR modulators: future prospects for treatment of cystic fibrosis","volume":"14","author":"Chaudary","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2024102404093150000_32.167.220154.26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0112-2019"},{"key":"2024102404093150000_32.167.220154.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.10.021"},{"key":"2024102404093150000_32.167.220154.28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17476348.2021.1855980","article-title":"Development of elexacaftor\u2013tezacaftor\u2013ivacaftor: highly effective CFTR modulation for the majority of people with cystic fibrosis","volume":"15","author":"Middleton","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2024102404093150000_32.167.220154.29","unstructured":"Cystic Fibrosis Foundation . CFTR Modulator Therapies. www.cff.org\/managing-cf\/cftr-modulator-therapies Date last accessed: 11 August 2022."},{"key":"2024102404093150000_32.167.220154.30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/jpm.2013.9515","article-title":"Palliative care for patients with cystic fibrosis #265","volume":"16","author":"Estrada-Veras","year":"2013","journal-title":"J Palliat Med"},{"key":"2024102404093150000_32.167.220154.31","unstructured":"Moffett KS . Pseudomonas aeruginosa in Patients with Cystic Fibrosis. www.antimicrobe.org\/new\/b260.asp Date last accessed: 11 August 2022."},{"key":"2024102404093150000_32.167.220154.32","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.60.3.539-574.1996"},{"key":"2024102404093150000_32.167.220154.33","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.112897"},{"key":"2024102404093150000_32.167.220154.34","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.9.732"},{"key":"2024102404093150000_32.167.220154.35","doi-asserted-by":"crossref","first-page":"1753466620905279","DOI":"10.1177\/1753466620905279","article-title":"Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin","volume":"14","author":"Akkerman-Nijland","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2024102404093150000_32.167.220154.36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline: pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2010","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404093150000_32.167.220154.37","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-09"},{"key":"2024102404093150000_32.167.220154.38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.39","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024102404093150000_32.167.220154.40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jcf.2020.07.004","article-title":"Ivacaftor or lumacaftor\/ivacaftor treatment does not alter the core CF airway epithelial gene response to rhinovirus","volume":"20","author":"De Jong","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/jcpt.12722","article-title":"Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa? Results of an in vitro study","volume":"43","author":"Millar","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2024102404093150000_32.167.220154.42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jcpt.12616","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with c.1652GA (G551D)-CFTR treated with ivacaftor \u2013 changes in microbiological parameters","volume":"43","author":"Millar","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2024102404093150000_32.167.220154.43","doi-asserted-by":"crossref","unstructured":"Aalbers B , Hoesein FM , Hofland R , et al. Correlation between chest CT findings and change in lung function on CFTR modulating treatment in CF patients. Authorea 2020; preprint [https:\/\/doi.org\/10.22541\/au.160439592.20308162\/v1].","DOI":"10.22541\/au.160439592.20308162\/v1"},{"key":"2024102404093150000_32.167.220154.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01918-2015"},{"key":"2024102404093150000_32.167.220154.45","doi-asserted-by":"crossref","first-page":"2101344","DOI":"10.1183\/13993003.01344-2021","article-title":"Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor\u2013ivacaftor in people with cystic fibrosis","volume":"18","author":"Campredon","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102404093150000_32.167.220154.46","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K"},{"key":"2024102404093150000_32.167.220154.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2005.05.009"},{"key":"2024102404093150000_32.167.220154.48","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.054726"},{"key":"2024102404093150000_32.167.220154.49","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","article-title":"Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin","volume":"10","author":"Ehsan","year":"2015","journal-title":"Future Microbiol"},{"key":"2024102404093150000_32.167.220154.50","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00467-015-3097-3","article-title":"Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis","volume":"30","author":"Downes","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2024102404093150000_32.167.220154.51","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.131532"},{"key":"2024102404093150000_32.167.220154.52","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.027953"},{"key":"2024102404093150000_32.167.220154.53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2024102404093150000_32.167.220154.54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1513\/AnnalsATS.201812-863OT","article-title":"Developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities","volume":"16","author":"Nichols","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404093150000_32.167.220154.55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"2024102404093150000_32.167.220154.56","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9910086"},{"key":"2024102404093150000_32.167.220154.57","unstructured":"Cystic Fibrosis Trust . Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. 2nd Edn. December 2011. www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/Cystic%20Fibrosis%20Trust%20Standards%20of%20care.pdf Date last accessed: 13 October 2022."},{"key":"2024102404093150000_32.167.220154.58","unstructured":"National Institute for Health and Care Excellence (NICE) . Cystic Fibrosis: Diagnosis and Management. www.nice.org.uk\/guidance\/ng78\/resources\/ Date last accessed: 13 October 2022. Date last updated: 25 October 2017."},{"key":"2024102404093150000_32.167.220154.59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.60","unstructured":"Bell SC , Robinson PJ . Cystic Fibrosis Standards of Care, Australia. 2008. https:\/\/thoracic.org.au\/wp-content\/uploads\/2022\/09\/CF_standardsofcare_Australia_2008.pdf Date last accessed: 13 October 2022."},{"key":"2024102404093150000_32.167.220154.61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404093150000_32.167.220154.62","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ppul.25248","article-title":"Epidemiologic study of cystic fibrosis: 25 years of observational research","volume":"56","author":"Konstan","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2024102404093150000_32.167.220154.63","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404093150000_32.167.220154.64","first-page":"S334","article-title":"Six-year follow-up of ivacaftor treated subjects with CFTRG551D: an update on the Dublin cohort","volume":"54","author":"Durfey","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2024102404093150000_32.167.220154.65","doi-asserted-by":"crossref","first-page":"e03148-21","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"2024102404093150000_32.167.220154.66","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024102404093150000_32.167.220154.67","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202010-1336SD"},{"key":"2024102404093150000_32.167.220154.68","unstructured":"ECFS Clinical Trials Network . CF STORM. www.cfstorm.org.uk\/ Date last accessed: 10 October 2022."},{"key":"2024102404093150000_32.167.220154.69","unstructured":"Qualitative Understanding of Experiences With the SIMPLIFY Trial (QUEST). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320381. Date last accessed: 11 August 2022. Date last updated: 29 March 2022."},{"key":"2024102404093150000_32.167.220154.70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"key":"2024102404093150000_32.167.220154.71","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.jcf.2022.02.012","article-title":"The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York","volume":"21","author":"Simonson","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0154-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:38Z","timestamp":1740373538000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0154-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":71,"journal-issue":{"issue":"167","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,3,31]]}},"alternative-id":["10.1183\/16000617.0154-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0154-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}